UBS Group’s Pacer BioThreat Strategy ETF VIRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-974
| Closed | -$38.8K | – | 10742 |
|
|
2024
Q3 | $38.8K | Buy |
974
+890
| +1,060% | +$33.9K | ﹤0.01% | 6985 |
|
|
2024
Q2 | $3.05K | Hold |
84
| – | – | ﹤0.01% | 8264 |
|
|
2024
Q1 | $3.04K | Sell |
84
-726
| -90% | -$24.9K | ﹤0.01% | 7781 |
|
|
2023
Q4 | $26.2K | Buy |
810
+610
| +305% | +$18.4K | ﹤0.01% | 6932 |
|
|
2023
Q3 | $5.96K | Buy |
+200
| New | +$6.25K | ﹤0.01% | 7330 |
|
|
2023
Q2 | – | Sell |
-8
| Closed | -$234 | – | 9903 |
|
|
2023
Q1 | $234 | Sell |
8
-4,616
| -100% | -$132K | ﹤0.01% | 9129 |
|
|
2022
Q4 | $131K | Buy |
4,624
+33
| +0.7% | +$913 | ﹤0.01% | 5848 |
|
|
2022
Q3 | $116K | Buy |
4,591
+4,130
| +896% | +$114K | ﹤0.01% | 5586 |
|
|
2022
Q2 | $12K | Sell |
461
-2
| -0.4% | -$57 | ﹤0.01% | 7697 |
|
|
2022
Q1 | $14K | Buy |
463
+335
| +262% | +$10.4K | ﹤0.01% | 7975 |
|
|
2021
Q4 | $4K | Sell |
128
-221
| -63% | -$7.51K | ﹤0.01% | 9565 |
|
|
2021
Q3 | $11K | Buy |
349
+226
| +184% | +$7.51K | ﹤0.01% | 7915 |
|
|
2021
Q2 | $4K | Buy |
+123
| New | +$3.74K | ﹤0.01% | 8715 |
|
UBS Group's VIRS Position: Q4 2024 in Review
UBS Group sold out of Pacer BioThreat Strategy ETF (VIRS) in Q4 2024, closing a stake of 974 shares — an estimated $38.8K sold.
UBS Group first reported a position in VIRS in Q2 2021 and held it in 13 quarters. The position peaked at $131K in Q4 2022. 0 funds tracked by Wall St. Rank hold VIRS as of Q4 2024.
- UBS Group reported no remaining Pacer BioThreat Strategy ETF position as of Q4 2024 after selling out during the quarter.
- UBS Group sold 974 Pacer BioThreat Strategy ETF shares in Q4 2024, an estimated $38.8K.
- UBS Group first reported a position in Pacer BioThreat Strategy ETF in Q2 2021 and held it in 13 quarters.
- UBS Group's Pacer BioThreat Strategy ETF position peaked at $131K in Q4 2022.
- 0 funds tracked by Wall St. Rank held Pacer BioThreat Strategy ETF as of Q4 2024.
Based on UBS Group's 13F filing for Q4 2024, filed 14 Feb 2025.